Einzeltreffer — DigiBib

Background: Is de novo metastatic breast cancer (dnMBC) the same disease in the elderly as in younger breast cancer remains unclear. This study aimed to determine the metastatic patterns and survival outcomes in dnMBC according to age groups.

Methods: We included patients from the Surveillance Epidemiology and End Results program. Chi-square test, multivariate logistic regression analyses, and multivariate Cox regression models were used for statistical analyses.

Results: A total of 17719 patients were included. There were 3.6% (n=638), 18.6% (n=3290), 38.0% (n=6725), and 39.9% (n=7066) of patients aged <35, 35-49, 50-64, and ≥65 years, respectively. Older patients had a significantly higher risk of lung metastasis and a significantly lower risk of liver metastasis. There were 19.1%, 25.6%, 30.9%, and 35.7% of patients with lung metastasis in those aged <35, 35-49, 50-64, and ≥65 years, respectively. Moreover, the proportion of liver metastasis was 37.6%, 29.5%, 26.3%, and 19.2%, respectively. Age was the independent prognostic factor associated with breast cancer-specific survival (BCSS) and overall survival (OS). Those aged 50-64 years had significantly inferior BCSS (P<0.001) and OS (P<0.001) than those aged <35 years. Patients aged ≥65 years also had significantly lower BCSS (P<0.001) and OS (P<0.001) than those aged <35 years. However, similar outcomes were found between those aged 35-49 and <35 years.

Conclusion: Our study suggests that different age groups may affect the metastatic patterns among patients with dnMBC and the survival of younger patients is more favorable than those of older patients.

Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Titel:	Patterns of distant metastasis and survival outcomes in de novo metastatic breast cancer according to age groups.
Autor/in / Beteiligte Person:	Liu, K ; Huang, AL ; Chen, XQ ; Wu, SG
Zeitschrift:	Frontiers in endocrinology, Jg. 15 (2024-05-01), S. 1385756
Veröffentlichung:	[Lausanne : Frontiers Research Foundation], 2024
Medientyp:	academicJournal
ISSN:	1664-2392 (print)
DOI:	10.3389/fendo.2024.1385756
Schlagwort:	Humans Female Middle Aged Aged Age Factors Adult Prognosis SEER Program Survival Rate Neoplasm Metastasis Breast Neoplasms pathology Breast Neoplasms mortality Lung Neoplasms mortality Lung Neoplasms pathology Lung Neoplasms secondary Liver Neoplasms secondary Liver Neoplasms mortality
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article Language: English [Front Endocrinol (Lausanne)] 2024 May 01; Vol. 15, pp. 1385756. <i>Date of Electronic Publication: </i>2024 May 01 (<i>Print Publication: </i>2024). MeSH Terms: Breast Neoplasms* / pathology ; Breast Neoplasms* / mortality ; Lung Neoplasms* / mortality ; Lung Neoplasms* / pathology ; Lung Neoplasms* / secondary ; Liver Neoplasms* / secondary ; Liver Neoplasms* / mortality ; Humans ; Female ; Middle Aged ; Aged ; Age Factors ; Adult ; Prognosis ; SEER Program ; Survival Rate ; Neoplasm Metastasis References: Support Care Cancer. 2019 Mar;27(3):879-885. (PMID: 30116944) ; Clin Cancer Res. 2021 Aug 1;27(15):4422-4434. (PMID: 34083229) ; CA Cancer J Clin. 2017 Nov;67(6):439-448. (PMID: 28972651) ; N Engl J Med. 2018 Jul 12;379(2):111-121. (PMID: 29860917) ; Breast. 2021 Aug;58:173-181. (PMID: 34158167) ; J Clin Oncol. 2013 Jul 1;31(19):2382-7. (PMID: 23690420) ; CA Cancer J Clin. 2022 Nov;72(6):524-541. (PMID: 36190501) ; J Cancer Res Clin Oncol. 2017 Mar;143(3):509-519. (PMID: 27853869) ; N Engl J Med. 2005 Oct 27;353(17):1784-92. (PMID: 16251534) ; Aging (Albany NY). 2022 Feb 8;14(3):1186-1199. (PMID: 35134749) ; J Am Coll Surg. 2009 Mar;208(3):341-7. (PMID: 19317994) ; Theranostics. 2016 Jan 25;6(3):435-45. (PMID: 26909117) ; Science. 2018 Sep 28;361(6409):. (PMID: 30262472) ; Breast Cancer Res Treat. 2018 Jan;167(2):579-590. (PMID: 29039120) ; JAMA. 2013 Feb 27;309(8):800-5. (PMID: 23443443) ; Ann Surg Oncol. 2021 Sep;28(9):5059-5070. (PMID: 33534046) ; CA Cancer J Clin. 2022 Jan;72(1):7-33. (PMID: 35020204) ; Lancet Oncol. 2015 Mar;16(3):266-73. (PMID: 25637340) ; Eur J Cancer. 2014 Jul;50(10):1697-1705. (PMID: 24768572) ; Front Endocrinol (Lausanne). 2023 Nov 06;14:1184895. (PMID: 38027167) ; CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338) ; Sci Rep. 2017 Aug 23;7(1):9254. (PMID: 28835702) ; Oncologist. 2020 Feb;25(2):e214-e222. (PMID: 32043771) ; N Engl J Med. 2010 Nov 11;363(20):1938-48. (PMID: 21067385) ; Respiration. 2014;87(6):508-12. (PMID: 24821602) ; J Clin Oncol. 2010 Jul 10;28(20):3271-7. (PMID: 20498394) ; Tumour Biol. 2017 Jun;39(6):1010428317705082. (PMID: 28653887) ; Jpn J Radiol. 2020 Nov;38(11):1062-1074. (PMID: 32562180) ; JMIR Res Protoc. 2017 Dec 18;6(12):e249. (PMID: 29254913) ; Breast Cancer Res Treat. 2019 Oct;177(3):713-722. (PMID: 31297648) ; PeerJ. 2019 Dec 03;7:e8163. (PMID: 31824772) ; Nature. 2015 Dec 17;528(7582):413-7. (PMID: 26649828) ; BMC Med. 2015 Oct 15;13:266. (PMID: 26467651) ; Breast Cancer (Dove Med Press). 2023 Oct 20;15:721-730. (PMID: 37881514) ; J Clin Oncol. 2022 Mar 20;40(9):978-987. (PMID: 34995128) ; ANZ J Surg. 2012 Jul-Aug;82(7-8):524-8. (PMID: 22776502) ; World J Surg Oncol. 2015 Feb 07;13:33. (PMID: 25889186) ; Lancet. 1993 Apr 24;341(8852):1039-43. (PMID: 8096955) ; Breast Cancer Res. 2020 Jun 15;22(1):64. (PMID: 32539762) ; Clin Geriatr Med. 2016 Feb;32(1):133-53. (PMID: 26614865) ; Cancer. 2018 Sep 1;124(17):3500-3509. (PMID: 30189117) ; Breast. 2017 Feb;31:1-8. (PMID: 27771499) ; BMC Med. 2023 Jul 3;21(1):240. (PMID: 37400830) ; Histopathology. 2018 Nov;73(5):717-731. (PMID: 29722058) ; J Cancer Res Clin Oncol. 2023 Aug;149(9):5665-5676. (PMID: 36538146) ; Lancet Oncol. 2015 Oct;16(13):1380-8. (PMID: 26363985) ; Cancer Manag Res. 2018 Sep 27;10:4005-4018. (PMID: 30310322) ; J Clin Oncol. 2007 Jun 10;25(17):2360-8. (PMID: 17515570) ; Cancer Med. 2018 Jul;7(7):3269-3277. (PMID: 29761914) ; Transl Cancer Res. 2021 Nov;10(11):4591-4600. (PMID: 35116316) ; PLoS One. 2014 Feb 24;9(2):e89389. (PMID: 24586742) Contributed Indexing: Keywords: SEER; age; breast cancer; metastatic patterns; prognosis Entry Date(s): Date Created: 20240516 Date Completed: 20240516 Latest Revision: 20240517 Update Code: 20240517 PubMed Central ID: PMC11094241

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Patterns of distant metastasis and survival outcomes in de novo metastatic breast cancer according to age groups.